drugset / Trial / NCT05442749
Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This trial is a single arm open-label, phase II aiming to assess the clinical activity of niraparib in chemotherapy-naïve biomarker-selected pancreatic cancer patients.
Timeline
- Start
- 2022-10-28
- Primary completion
- 2024-08-30
- Completion
- 2024-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | 300 mg | Oral |